Humacyte
HUMA
156 hedge funds and large institutions have $119M invested in Humacyte in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 73 increasing their positions, 26 reducing their positions, and 40 closing their positions.
181% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 26
14% more capital invested
Capital invested by funds: $104M → $119M (+$14.9M)
8% less call options, than puts
Call options by funds: $2.94M | Put options by funds: $3.21M
2.9% less ownership
Funds ownership: 39.58% → 36.69% (-2.9%)
7% less funds holding
Funds holding: 168 → 156 (-12)
23% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 40
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$4.98M |
| 2 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$3.86M |
| 3 |
BlackRock
New York
|
+$3.3M |
| 4 |
Millennium Management
New York
|
+$2.33M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
-$6.86M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.65M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.39M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$3.74M |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$3.63M |
HUMA Hedge Fund Activity: Q2 2025 in Review
156 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q2 2025, worth a combined $119M — up 14% from $104M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of HUMA and 31 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 73 added.
The largest buyer was Marshall Wace, adding an estimated $4.98M. The largest seller was Heights Capital Management, exiting entirely with an estimated $6.86M sold.
- 156 institutional investors held Humacyte (HUMA) as of Q2 2025, down from 168 in Q1 2025.
- Funds reported $119M of Humacyte stock for Q2 2025, up 14% quarter-over-quarter.
- 31 funds opened new Humacyte positions in Q2 2025 and 40 closed out, a net change of -9 holders.
- The largest Humacyte buyer in Q2 2025 was Marshall Wace, an estimated $4.98M added.
- The largest Humacyte seller in Q2 2025 was Heights Capital Management, an estimated $6.86M sold.
Based on aggregated 13F filings for Q2 2025.